This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, L. Articles by Carter, C. Search for Related Content PubMed PubMed Citation Articles by Liu, L. Articles by Carter, C.

Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5

Department of Cancer Biology, Bayer HealthCare Pharmaceuticals, West Haven, Connecticut

Requests for reprints: Li Liu, Department of Cancer Biology, Bayer HealthCare Pharmaceuticals, 400 Morgan Lane, West Haven, CT 06516. Phone: 203-812-6724; Fax: 203-203-6923; E-mail: li.liu.b{at}bayer.com.

Angiogenesis and signaling through the RAF/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK cascade have been reported to play important roles in the development of hepatocellular carcinomas (HCC). Sorafenib (BAY 43-9006, Nexavar) is a multikinase inhibitor with activity against Raf kinase and several receptor tyrosine kinases, including vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), FLT3, Ret, and c-Kit. In this study, we investigated the in vitro effects of sorafenib on PLC/PRF/5 and HepG2 HCC cells and the in vivo antitumor efficacy and mechanism of action on PLC/PRF/5 human tumor xenografts in severe combined immunodeficient mice. Sorafenib inhibited the phosphorylation of MEK and ERK and down-regulated cyclin D1 levels in these two cell lines. Sorafenib also reduced the phosphorylation level of eIF4E and down-regulated the antiapoptotic protein Mcl-1 in a MEK/ERK–independent manner. Consistent with the effects on both MEK/ERK–dependent and MEK/ERK–independent signaling pathways, sorafenib inhibited proliferation and induced apoptosis in both HCC cell lines. In the PLC/PRF/5 xenograft model, sorafenib tosylate dosed at 10 mg/kg inhibited tumor growth by 49%. At 30 mg/kg, sorafenib tosylate produced complete tumor growth inhibition. A dose of 100 mg/kg produced partial tumor regressions in 50% of the mice. In mechanism of action studies, sorafenib inhibited the phosphorylation of both ERK and eIF4E, reduced the microvessel area (assessed by CD34 immunohistochemistry), and induced tumor cell apoptosis (assessed by terminal deoxynucleotidyl transferase–mediated nick end labeling) in PLC/PRF/5 tumor xenografts. These results suggest that the antitumor activity of sorafenib in HCC models may be attributed to inhibition of tumor angiogenesis (VEGFR and PDGFR) and direct effects on tumor cell proliferation/survival (Raf kinase signaling-dependent and signaling-independent mechanisms). (Cancer Res 2006; 66(24): 11851-8)

This article has been cited by other articles:

				K Himmelsbach, D Sauter, T F Baumert, L Ludwig, H E Blum, and E Hildt New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication Gut, December 1, 2009; 58(12): 1644 - 1653. [Abstract] [Full Text] [PDF]

				L. Caja, P. Sancho, E. Bertran, D. Iglesias-Serret, J. Gil, and I. Fabregat Overactivation of the MEK/ERK Pathway in Liver Tumor Cells Confers Resistance to TGF-{beta}-Induced Cell Death through Impairing Up-regulation of the NADPH Oxidase NOX4 Cancer Res., October 1, 2009; 69(19): 7595 - 7602. [Abstract] [Full Text] [PDF]

				D.-L. Ou, Y.-C. Shen, J.-D. Liang, J.-Y. Liou, S.-L. Yu, H.-H. Fan, D.-S. Wang, Y.-S. Lu, C. Hsu, and A.-L. Cheng Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma Clin. Cancer Res., September 15, 2009; 15(18): 5820 - 5828. [Abstract] [Full Text] [PDF]

				G. R. Blumenschein Jr, U. Gatzemeier, F. Fossella, D. J. Stewart, L. Cupit, F. Cihon, J. O'Leary, and M. Reck Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 10, 2009; 27(26): 4274 - 4280. [Abstract] [Full Text] [PDF]

				S. Yang, V. C. Ngo, G. B. Lew, L. W. V. Chong, S. S. Lee, W. J. R. Ong, W. L. I. Lam, C. H. Thng, H. N. Koong, H. S. Ong, et al. AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer Mol. Cancer Ther., September 1, 2009; 8(9): 2537 - 2545. [Abstract] [Full Text] [PDF]

				K. Takezawa, I. Okamoto, K. Yonesaka, E. Hatashita, Y. Yamada, M. Fukuoka, and K. Nakagawa Sorafenib Inhibits Non-Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells Cancer Res., August 15, 2009; 69(16): 6515 - 6521. [Abstract] [Full Text] [PDF]

				A. Komuro, M. Yashiro, C. Iwata, Y. Morishita, E. Johansson, Y. Matsumoto, A. Watanabe, H. Aburatani, H. Miyoshi, K. Kiyono, et al. Diffuse-Type Gastric Carcinoma: Progression, Angiogenesis, and Transforming Growth Factor {beta} Signaling J Natl Cancer Inst, April 15, 2009; 101(8): 592 - 604. [Abstract] [Full Text] [PDF]

				F. Illouz, S. Laboureau-Soares, S. Dubois, V. Rohmer, and P. Rodien Tyrosine kinase inhibitors and modifications of thyroid function tests: a review Eur. J. Endocrinol., March 1, 2009; 160(3): 331 - 336. [Abstract] [Full Text] [PDF]

				U. Basso, A. Brunello, A. Bertuzzi, and A. Santoro Sorafenib is active on lung metastases from synovial sarcoma Ann. Onc., February 1, 2009; 20(2): 386 - 387. [Full Text] [PDF]

				M. Pinter, W. Sieghart, I. Graziadei, W. Vogel, A. Maieron, R. Konigsberg, A. Weissmann, G. Kornek, C. Plank, and M. Peck-Radosavljevic Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis Oncologist, January 1, 2009; 14(1): 70 - 76. [Abstract] [Full Text] [PDF]

				R. K. Kelley and A. P. Venook Sorafenib in Hepatocellular Carcinoma: Separating the Hype From the Hope J. Clin. Oncol., December 20, 2008; 26(36): 5845 - 5848. [Full Text] [PDF]

				F. Yang, T. E. Van Meter, R. Buettner, M. Hedvat, W. Liang, C. M. Kowolik, N. Mepani, J. Mirosevich, S. Nam, M. Y. Chen, et al. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas Mol. Cancer Ther., November 1, 2008; 7(11): 3519 - 3526. [Abstract] [Full Text] [PDF]

				M. E. Lacouture, L. M. Reilly, P. Gerami, and J. Guitart Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib Ann. Onc., November 1, 2008; 19(11): 1955 - 1961. [Abstract] [Full Text] [PDF]

				S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol. Cancer Ther., October 1, 2008; 7(10): 3129 - 3140. [Abstract] [Full Text] [PDF]

				M. E. Lacouture, S. Wu, C. Robert, M. B. Atkins, H. H. Kong, J. Guitart, C. Garbe, A. Hauschild, I. Puzanov, D. T. Alexandrescu, et al. Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib Oncologist, September 1, 2008; 13(9): 1001 - 1011. [Abstract] [Full Text] [PDF]

				J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.-F. Blanc, A. C. de Oliveira, A. Santoro, J.-L. Raoul, A. Forner, et al. Sorafenib in Advanced Hepatocellular Carcinoma N. Engl. J. Med., July 24, 2008; 359(4): 378 - 390. [Abstract] [Full Text] [PDF]

				T. Yi, S.-G. Cho, Z. Yi, X. Pang, M. Rodriguez, Y. Wang, G. Sethi, B. B. Aggarwal, and M. Liu Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways Mol. Cancer Ther., July 1, 2008; 7(7): 1789 - 1796. [Abstract] [Full Text] [PDF]

				H. Tatebe, M. Shimizu, Y. Shirakami, H. Tsurumi, and H. Moriwaki Synergistic Growth Inhibition by 9-cis-Retinoic Acid Plus Trastuzumab in Human Hepatocellular Carcinoma Cells Clin. Cancer Res., May 1, 2008; 14(9): 2806 - 2812. [Abstract] [Full Text] [PDF]

				R. R. Rosato, J. A. Almenara, S. Coe, and S. Grant The Multikinase Inhibitor Sorafenib Potentiates TRAIL Lethality in Human Leukemia Cells in Association with Mcl-1 and cFLIPL Down-regulation Cancer Res., October 1, 2007; 67(19): 9490 - 9500. [Abstract] [Full Text] [PDF]

				G. Dasmahapatra, N. Yerram, Y. Dai, P. Dent, and S. Grant Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation Clin. Cancer Res., July 15, 2007; 13(14): 4280 - 4290. [Abstract] [Full Text] [PDF]